Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus
Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated t...
Saved in:
Published in | Liver international Vol. 39; no. 5; pp. 967 - 975 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.05.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 1478-3223 1478-3231 1478-3231 |
DOI | 10.1111/liv.14069 |
Cover
Abstract | Background and Aims
Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.
Methods
We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.
Results
In PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).
Conclusions
Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition. |
---|---|
AbstractList | Background and AimsPruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.MethodsWe studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.ResultsIn PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).ConclusionsPruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition. Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing. In PBC patients with pruritus, serum levels of total and glyco-conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04). Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition. Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.BACKGROUND AND AIMSPruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.METHODSWe studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.In PBC patients with pruritus, serum levels of total and glyco-conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).RESULTSIn PBC patients with pruritus, serum levels of total and glyco-conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.CONCLUSIONSPruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition. Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. Methods We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing. Results In PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04). Conclusions Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition. |
Author | Hegade, Vinod S. Jones, David E. Pechlivanis, Alexandros Holmes, Elaine McDonald, Julie A. K. Kendrick, Stuart Taylor‐Robinson, Simon D. Hirschfield, Gideon M. Corrigan, Margaret Rees, Douglas Marchesi, Julian R. |
Author_xml | – sequence: 1 givenname: Vinod S. orcidid: 0000-0001-9572-2361 surname: Hegade fullname: Hegade, Vinod S. email: vinod.hegade@newcastle.ac.uk organization: Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University – sequence: 2 givenname: Alexandros surname: Pechlivanis fullname: Pechlivanis, Alexandros organization: Imperial College London – sequence: 3 givenname: Julie A. K. surname: McDonald fullname: McDonald, Julie A. K. organization: Imperial College London – sequence: 4 givenname: Douglas surname: Rees fullname: Rees, Douglas organization: Imperial College London – sequence: 5 givenname: Margaret surname: Corrigan fullname: Corrigan, Margaret organization: University of Birmingham – sequence: 6 givenname: Gideon M. surname: Hirschfield fullname: Hirschfield, Gideon M. organization: University of Birmingham – sequence: 7 givenname: Simon D. surname: Taylor‐Robinson fullname: Taylor‐Robinson, Simon D. organization: Imperial College London – sequence: 8 givenname: Elaine surname: Holmes fullname: Holmes, Elaine organization: Imperial College London – sequence: 9 givenname: Julian R. surname: Marchesi fullname: Marchesi, Julian R. organization: Cardiff University – sequence: 10 givenname: Stuart surname: Kendrick fullname: Kendrick, Stuart organization: GlaxoSmithKline (GSK), Research and Development – sequence: 11 givenname: David E. surname: Jones fullname: Jones, David E. organization: Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30735608$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kV1LBCEUhiWKvi_6AyF0U9CWOq7OXEb0BQvdRLeijrbGrG7q9PEL-ts57RYRlDfnqM97OOe8W2DVB28A2MPoBJdz2rnnE0wRa1bAJqa8HlWkwqvfOak2wFZKjwjhphnjdbBRIV6NGao3wftZn0OWr84fQ-U6A6V2LZzHYD8vvoXGWqMzDBaWF9n9oHKUPs1DzCZC56dOueyCL2nRu5mMbwPrhqinoZP-ofwnOJfZGZ8TfHF5Wsg-utynHbBmZZfM7jJug7vLi7vz69Hk9urm_Gwy0lVdNyNMMbVMaooJZUpZwxU1VilKjeZGEU04aVqruawZ4S1BNcFjzqi0miGqq21wuChbJnzqTcpi5pI2XenOhD4JgmuGKavHpKAHv9DH0EdfmhOE4IrTASrU_pLq1cy0Yjm5-NpwAY4WgI4hpWjsN4KRGNwTxT3x6V5hT3-x2mU5LLWs2nX_KV6KK29_lxaTm_uF4gOUa60F |
CitedBy_id | crossref_primary_10_3389_fmed_2021_639674 crossref_primary_10_3390_nu13031018 crossref_primary_10_1007_s11901_020_00517_x crossref_primary_10_26416_Aler_8_3_2024_10138 crossref_primary_10_1016_j_gastre_2020_08_002 crossref_primary_10_1016_j_biopha_2020_110835 crossref_primary_10_1007_s40257_022_00710_2 crossref_primary_10_1111_eci_13714 crossref_primary_10_17816_dv635963 crossref_primary_10_3390_ijms26051883 crossref_primary_10_1016_j_bbadis_2020_165958 crossref_primary_10_1016_j_cld_2022_06_003 crossref_primary_10_1016_j_jacbts_2020_10_001 crossref_primary_10_1097_HEP_0000000000000728 crossref_primary_10_1016_j_cgh_2022_10_032 crossref_primary_10_1055_s_0044_1787705 crossref_primary_10_1016_j_jhep_2021_08_025 crossref_primary_10_1007_s11894_019_0713_6 crossref_primary_10_7861_clinmed_2021_0725 crossref_primary_10_1016_S2352_4642_23_00259_6 crossref_primary_10_1080_13543784_2024_2343789 crossref_primary_10_1124_dmd_121_000595 crossref_primary_10_1111_liv_14553 crossref_primary_10_3390_gastroent15020030 crossref_primary_10_1016_j_cld_2022_06_009 crossref_primary_10_1111_liv_15982 crossref_primary_10_1016_j_cca_2024_120004 crossref_primary_10_1111_liv_15030 crossref_primary_10_1016_j_gastrohep_2020_08_001 crossref_primary_10_3390_ijms25084321 |
Cites_doi | 10.1038/nrgastro.2015.46 10.1136/gut.2005.065862 10.1016/j.cbi.2015.08.016 10.1002/hep4.1209 10.1038/msb.2008.56 10.1016/j.autrev.2016.03.019 10.1016/j.dld.2011.10.025 10.1038/s41598-018-25214-0 10.1016/j.jhep.2017.03.022 10.1111/apt.13794 10.3892/ijmm.2015.2233 10.1002/hep.25748 10.1021/acs.analchem.5b01556 10.1111/liv.12680 10.1053/j.gastro.2010.05.009 10.1097/MOG.0000000000000057 10.1073/pnas.1006734107 10.1111/j.1365-2133.2009.09586.x 10.1016/S0168-8278(16)00146-X 10.1016/j.clinbiochem.2006.10.009 10.1038/ncomms11248 10.1053/j.gastro.2011.07.046 10.1136/gutjnl-2015-309618 10.1016/j.cgh.2018.12.007 10.1001/archinte.1972.03650040156014 10.1159/000450988 10.1371/journal.pone.0178580 10.1111/1462-2920.13401 10.1016/S0140-6736(17)30319-7 10.1016/j.autrev.2017.07.002 10.1002/hep.27973 10.1038/nrgastro.2015.114 10.1093/ajcn/27.11.1341 10.1136/gut.12.2.145 10.1016/j.jhep.2015.10.024 10.1136/gutjnl-2016-313332 10.1186/s12876-016-0481-9 10.1016/S0168-8278(16)00697-8 10.1111/j.1572-0241.2007.01200.x |
ContentType | Journal Article |
Copyright | 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2019 John Wiley & Sons A/S |
Copyright_xml | – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2019 John Wiley & Sons A/S |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
DOI | 10.1111/liv.14069 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | Genetics Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1478-3231 |
EndPage | 975 |
ExternalDocumentID | 30735608 10_1111_liv_14069 LIV14069 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: GlaxoSmithKline (GSK) – fundername: National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre – fundername: Medical Research Council grantid: MR/L001489/1 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3889-1414f6ac41246bbfe7b4efbb44ec7eb2c2729dfc7a8627d208215764afc604c3 |
IEDL.DBID | DR2 |
ISSN | 1478-3223 1478-3231 |
IngestDate | Fri Sep 05 06:07:10 EDT 2025 Wed Aug 13 07:41:51 EDT 2025 Mon Jul 21 06:02:47 EDT 2025 Wed Oct 01 04:49:30 EDT 2025 Thu Apr 24 22:53:08 EDT 2025 Sun Sep 21 06:17:43 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | PBC microbiota pruritus metabonome |
Language | English |
License | 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3889-1414f6ac41246bbfe7b4efbb44ec7eb2c2729dfc7a8627d208215764afc604c3 |
Notes | Funding information This study was funded via the research grant from the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre. BAT117213 sample collection was funded by GlaxoSmithKline (GSK). This paper presents independent research and the views expressed are those of the authors and not necessarily those of the NIHR or GSK. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-9572-2361 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.14069 |
PMID | 30735608 |
PQID | 2213748523 |
PQPubID | 2045125 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2186146852 proquest_journals_2213748523 pubmed_primary_30735608 crossref_primary_10_1111_liv_14069 crossref_citationtrail_10_1111_liv_14069 wiley_primary_10_1111_liv_14069_LIV14069 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2019 2019-05-00 20190501 |
PublicationDateYYYYMMDD | 2019-05-01 |
PublicationDate_xml | – month: 05 year: 2019 text: May 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Liver international |
PublicationTitleAlternate | Liver Int |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2015; 35 2015; 12 2015; 36 2007; 102 2017; 67 1972; 130 2010; 162 2008; 4 2016; 18 2018; 67 2012; 56 2016; 16 2016; 15 2014; 60 1974; 27 2018; 8 2016; 7 2018; 2 2011; 108 2010; 139 2017; 16 1971; 12 2017; 35 1984; 6 2015; 87 2017; 12 2016; 65 2016; 64 2016; 255 2018 2016; 63 2005; 54 2007; 40 2011; 141 2014; 30 2017; 389 2012; 44 2016; 44 e_1_2_9_30_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 Pares A (e_1_2_9_18_1) 2014; 60 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_41_1 e_1_2_9_42_1 e_1_2_9_20_1 e_1_2_9_40_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Padova C (e_1_2_9_31_1) 1984; 6 Herndon JH (e_1_2_9_5_1) 1972; 130 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 Reig A (e_1_2_9_19_1) 2016; 64 e_1_2_9_29_1 |
References_xml | – volume: 6 start-page: 773 issue: 12 year: 1984 end-page: 776 article-title: Double‐blind placebo‐controlled clinical trial of microporous cholestyramine in the treatment of intra‐ and extra‐hepatic cholestasis: relationship between itching and serum bile acids publication-title: Methods Find Exp Clin Pharmacol – volume: 102 start-page: 1528 issue: 7 year: 2007 end-page: 1536 article-title: The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis‐associated pruritus publication-title: Am J Gastroenterol – volume: 67 start-page: 145 year: 2017 end-page: 172 article-title: EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis publication-title: J Hepatol – volume: 44 start-page: 303 issue: 4 year: 2012 end-page: 310 article-title: Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study publication-title: Dig Liver Dis – volume: 12 start-page: e0178580 issue: 6 year: 2017 article-title: Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis publication-title: PLoS ONE – volume: 65 start-page: 57 issue: 1 year: 2016 end-page: 62 article-title: Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates publication-title: Gut – volume: 35 start-page: 267 issue: 3 year: 2017 end-page: 274 article-title: Apical sodium‐dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis publication-title: Digestive diseases (Basel, Switzerland) – volume: 87 start-page: 9662 issue: 19 year: 2015 end-page: 9670 article-title: Bile acid profiling and quantification in biofluids using ultra‐performance liquid chromatography tandem mass spectrometry publication-title: Anal Chem – year: 2018 article-title: Pruritus is common and under-treated in patients with primary biliary cholangitis in the United Kingdom publication-title: Clin Gastroenterol Hepatol – volume: 2 start-page: 1037 issue: 9 year: 2018 end-page: 1050 article-title: NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled trial publication-title: Hepatol Commun – volume: 130 start-page: 632 issue: 4 year: 1972 end-page: 637 article-title: Pathophysiology of pruritus associated with elevated bile acid levels in serum publication-title: Arch Intern Med – volume: 40 start-page: 274 issue: 3–4 year: 2007 end-page: 277 article-title: Measurement of lysophospholipase D/autotaxin activity in human serum samples publication-title: Clin Biochem – volume: 60 start-page: 358A year: 2014 article-title: Circulating bile acids and sterol levels in patients with cholestatic pruritus. Effects of albumin dialysis using Mars: 313 publication-title: Hepatology – volume: 12 start-page: 253 issue: 5 year: 2015 end-page: 254 article-title: Gut microbiota: Optimal sampling of the intestinal microbiota for research publication-title: Nat Rev Gastroenterol Hepatol – volume: 12 start-page: 145 issue: 2 year: 1971 end-page: 152 article-title: Serum bile acids in liver disease publication-title: Gut – volume: 12 start-page: 458 issue: 8 year: 2015 end-page: 471 article-title: The promise of metabolic phenotyping in gastroenterology and hepatology publication-title: Nat Rev Gastroenterol Hepatol – volume: 36 start-page: 377 issue: 2 year: 2015 end-page: 385 article-title: Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis publication-title: Int J Mol Med – volume: 141 start-page: 1773 issue: 5 year: 2011 end-page: 1781 article-title: Bile acid is a host factor that regulates the composition of the cecal microbiota in rats publication-title: Gastroenterology – volume: 64 start-page: S197 issue: 2 year: 2016 article-title: Clarity: a phase 2, randomized, double‐blind, placebo‐controlled study of lopixibat chloride (Formerly Lum001), a novel apical sodium‐dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching publication-title: J Hepatol – volume: 64 start-page: S429 issue: 2 year: 2016 article-title: Bezafibrate alleviates pruritus and decreases specific circulating metabolites in patients with primary biliary cholangitis publication-title: J Hepatol – volume: 162 start-page: 587 issue: 3 year: 2010 end-page: 593 article-title: The 5‐D itch scale: a new measure of pruritus publication-title: Br J Dermatol – volume: 18 start-page: 2272 issue: 7 year: 2016 end-page: 2286 article-title: Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis publication-title: Environ Microbiol – volume: 139 start-page: 1008 issue: 3 year: 2010 end-page: 1018 article-title: Lysophosphatidic acid is a potential mediator of cholestatic pruritus publication-title: Gastroenterology – volume: 56 start-page: 1391 issue: 4 year: 2012 end-page: 1400 article-title: Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions publication-title: Hepatology – volume: 8 start-page: 6658 issue: 1 year: 2018 article-title: Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis publication-title: Sci Rep – volume: 16 start-page: 885 issue: 9 year: 2017 end-page: 896 article-title: Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases publication-title: Autoimmun Rev – volume: 255 start-page: 83 year: 2016 end-page: 91 article-title: Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis publication-title: Chem Biol Interact – volume: 44 start-page: 1039 issue: 10 year: 2016 end-page: 1050 article-title: The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis publication-title: Aliment Pharmacol Ther – volume: 27 start-page: 1341 issue: 11 year: 1974 end-page: 1347 article-title: Microbial bile acid transformation publication-title: Am J Clin Nutr – volume: 54 start-page: 1622 issue: 11 year: 2005 end-page: 1629 article-title: Development, validation, and evaluation of the PBC‐40, a disease specific health related quality of life measure for primary biliary cirrhosis publication-title: Gut – volume: 67 start-page: 534 issue: 3 year: 2018 end-page: 541 article-title: Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy publication-title: Gut – volume: 7 start-page: 11248 year: 2016 article-title: Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling publication-title: Nat Commun – volume: 30 start-page: 332 issue: 3 year: 2014 end-page: 338 article-title: Bile acids and the gut microbiome publication-title: Curr Opin Gastroenterol – volume: 389 start-page: 1114 issue: 10074 year: 2017 end-page: 1123 article-title: Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double‐blind, randomised, placebo‐controlled, crossover, phase 2a study publication-title: Lancet – volume: 4 start-page: 219 year: 2008 article-title: Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes publication-title: Mol Syst Biol – volume: 35 start-page: 263 issue: 1 year: 2015 end-page: 274 article-title: Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis publication-title: Liver Int – volume: 108 start-page: 4523 issue: Suppl 1 year: 2011 end-page: 4530 article-title: Systemic gut microbial modulation of bile acid metabolism in host tissue compartments publication-title: Proc Natl Acad Sci U S A – volume: 63 start-page: 512 issue: 2 year: 2016 end-page: 523 article-title: Pharmacological inhibition of apical sodium‐dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice publication-title: Hepatology – volume: 16 start-page: 71 issue: 1 year: 2016 article-title: BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial publication-title: BMC Gastroenterol – volume: 64 start-page: 674 issue: 3 year: 2016 end-page: 681 article-title: Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis publication-title: J Hepatol – volume: 15 start-page: 795 issue: 8 year: 2016 end-page: 800 article-title: Autotaxin, pruritus and primary biliary cholangitis (PBC) publication-title: Autoimmun Rev – ident: e_1_2_9_41_1 doi: 10.1038/nrgastro.2015.46 – ident: e_1_2_9_25_1 doi: 10.1136/gut.2005.065862 – ident: e_1_2_9_17_1 doi: 10.1016/j.cbi.2015.08.016 – ident: e_1_2_9_28_1 doi: 10.1002/hep4.1209 – ident: e_1_2_9_37_1 doi: 10.1038/msb.2008.56 – ident: e_1_2_9_6_1 doi: 10.1016/j.autrev.2016.03.019 – ident: e_1_2_9_14_1 doi: 10.1016/j.dld.2011.10.025 – ident: e_1_2_9_10_1 doi: 10.1038/s41598-018-25214-0 – ident: e_1_2_9_2_1 doi: 10.1016/j.jhep.2017.03.022 – ident: e_1_2_9_4_1 doi: 10.1111/apt.13794 – ident: e_1_2_9_16_1 doi: 10.3892/ijmm.2015.2233 – ident: e_1_2_9_7_1 doi: 10.1002/hep.25748 – ident: e_1_2_9_26_1 doi: 10.1021/acs.analchem.5b01556 – ident: e_1_2_9_15_1 doi: 10.1111/liv.12680 – ident: e_1_2_9_33_1 doi: 10.1053/j.gastro.2010.05.009 – ident: e_1_2_9_35_1 doi: 10.1097/MOG.0000000000000057 – ident: e_1_2_9_38_1 doi: 10.1073/pnas.1006734107 – volume: 60 start-page: 358A year: 2014 ident: e_1_2_9_18_1 article-title: Circulating bile acids and sterol levels in patients with cholestatic pruritus. Effects of albumin dialysis using Mars: 313 publication-title: Hepatology – ident: e_1_2_9_24_1 doi: 10.1111/j.1365-2133.2009.09586.x – ident: e_1_2_9_9_1 doi: 10.1016/S0168-8278(16)00146-X – ident: e_1_2_9_27_1 doi: 10.1016/j.clinbiochem.2006.10.009 – ident: e_1_2_9_34_1 doi: 10.1038/ncomms11248 – ident: e_1_2_9_22_1 doi: 10.1053/j.gastro.2011.07.046 – volume: 6 start-page: 773 issue: 12 year: 1984 ident: e_1_2_9_31_1 article-title: Double‐blind placebo‐controlled clinical trial of microporous cholestyramine in the treatment of intra‐ and extra‐hepatic cholestasis: relationship between itching and serum bile acids publication-title: Methods Find Exp Clin Pharmacol – ident: e_1_2_9_42_1 doi: 10.1136/gutjnl-2015-309618 – ident: e_1_2_9_3_1 doi: 10.1016/j.cgh.2018.12.007 – volume: 130 start-page: 632 issue: 4 year: 1972 ident: e_1_2_9_5_1 article-title: Pathophysiology of pruritus associated with elevated bile acid levels in serum publication-title: Arch Intern Med doi: 10.1001/archinte.1972.03650040156014 – ident: e_1_2_9_11_1 doi: 10.1159/000450988 – ident: e_1_2_9_29_1 doi: 10.1371/journal.pone.0178580 – ident: e_1_2_9_20_1 doi: 10.1111/1462-2920.13401 – ident: e_1_2_9_12_1 doi: 10.1016/S0140-6736(17)30319-7 – ident: e_1_2_9_36_1 doi: 10.1016/j.autrev.2017.07.002 – ident: e_1_2_9_39_1 doi: 10.1002/hep.27973 – ident: e_1_2_9_13_1 doi: 10.1038/nrgastro.2015.114 – ident: e_1_2_9_23_1 doi: 10.1093/ajcn/27.11.1341 – ident: e_1_2_9_30_1 doi: 10.1136/gut.12.2.145 – ident: e_1_2_9_40_1 doi: 10.1016/j.jhep.2015.10.024 – ident: e_1_2_9_21_1 doi: 10.1136/gutjnl-2016-313332 – ident: e_1_2_9_8_1 doi: 10.1186/s12876-016-0481-9 – volume: 64 start-page: S429 issue: 2 year: 2016 ident: e_1_2_9_19_1 article-title: Bezafibrate alleviates pruritus and decreases specific circulating metabolites in patients with primary biliary cholangitis publication-title: J Hepatol doi: 10.1016/S0168-8278(16)00697-8 – ident: e_1_2_9_32_1 doi: 10.1111/j.1572-0241.2007.01200.x |
SSID | ssj0019951 |
Score | 2.4197276 |
Snippet | Background and Aims
Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is... Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a... Background and AimsPruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 967 |
SubjectTerms | Acids Adult Aged Bile Bile acids Bile Acids and Salts - blood Biomarkers - blood Carrier Proteins Case-Control Studies Chenodeoxycholic acid Chenodeoxycholic Acid - pharmacology Cholangitis Cholic acid Cholic Acid - pharmacology Chromatography, Liquid Feces - chemistry Feces - microbiology Female Gene sequencing Humans Inhibition Intestinal microflora Liquid chromatography Liver Cirrhosis, Biliary - complications Male Mass spectrometry Mass spectroscopy Membrane Glycoproteins metabonome Methylamines - pharmacology Microbiomes Microbiota Middle Aged PBC Phosphoric Diester Hydrolases - blood Pruritus Pruritus - blood Pruritus - drug therapy Pruritus - etiology Relative abundance Ribonucleic acid RNA RNA, Ribosomal, 16S - genetics rRNA 16S Serum levels Tandem Mass Spectrometry Thiazepines - pharmacology |
Title | Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.14069 https://www.ncbi.nlm.nih.gov/pubmed/30735608 https://www.proquest.com/docview/2213748523 https://www.proquest.com/docview/2186146852 |
Volume | 39 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1478-3231 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0019951 issn: 1478-3223 databaseCode: ABDBF dateStart: 20030201 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1478-3223 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1478-3231 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0019951 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9VAEJ4QTIwvoqByEMlCjPGBQ3rZbnvi00E8QQM8ECQ8mDS7293QAD0JbYn6B_zbzmy3FbwkxKdu2ml2285059uZ_QbgdRboIjaIThIpxZhrbBEnCOpyNsl0FGjuwgWHR2L_M_90lpwtwLt-L0zHDzEsuJFluP81GbhU9S0jvyxv0MwDQZv3wjhxIdrjgTqKdh47sMUp_I9zoGcVoiye4c67c9EfDuZdf9VNOLMl-NIPtcszudhpG7Wjv__G4vifz_IEHntHlE07zXkKC6ZahpVphSD86ht7w1xqqFtzX4aHhz4CvwI_pm0zb-TXstpmCvtiUpcF85W_mawK1mWIsLlleAZ7-CXVDETq16yszkvl0sWwifc7zguSLenoEDdVUipr5plfa0ZLxihJ5fba-hmczD6cvN8f-2IOYx1TJlXIQ26F1FTtWihlTaq4sUpxbnSK8F5H6OYXVqcSMVZaROiahIiFuLRaBFzHz2GxmldmFZhVRmRpzHVgQq6KYBJrHhRWWSkSGwfRCN72XzXXnuic6m1c5j3gwdedu9c9gq1B1D_p34TWe9XIvYHXeRSFRNyDMH4Em8NlNE2Kt8jKzFuUCTNBO9sSHNKLTqWGXujXis5mhoN1ivHv7vODj6eusXZ_0ZfwCB27SZeYuQ6LzXVrXqHz1KgNeDDd3dudbThr-QlPTxiT |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIcFeBqwwCgMMQogHOuXDdVJpLxVQFWj7gAraC4psx9aijVRakwn4B_Zv785xMsaHhHiKk1xkO7mL72effwfwPA10HhtEJ0MpxYBrLBEnCOpyOkp1FGjulgvmCzH9xN8fDg834KDdC9PwQ3QTbmQZ7n9NBk4T0j9Z-UlxhnYeiNE1uE7rc2SWbz525FG099jBLU4BADgKel4hiuPpHr06Gv3mYl71WN2QM7kFX9rGNpEmx_t1pfb1j194HP-3N7dh2_uibNwozx3YMOUO9MYl4vCv39kL5qJD3bT7DtyY-0X4HpyP62pVyW9F-YoprIxJXeTMJ_9mssxZEyTCVpbhFazhUqrquNRPWVEeFcpFjGERn3e0FyRb0NGBbkqmVKyZJ39dM5o1RknKuFev78Jy8nb5ejrw-RwGOqZgqpCH3AqpKeG1UMqaRHFjleLc6AQRvo7Q08-tTiTCrCSP0DsJEQ5xabUIuI7vwWa5Ks19YFYZkSYx14EJucqDUax5kFtlpRjaOIj68LL9rJn2XOeUcuMkazEPvu7Mve4-POtEfU__JLTX6kbmbXydRVFI3D2I5PvwtLuN1klLLrI0qxplwlTQ5rYhNmm30amuFvq7or-ZYmOdZvy9-mz27rMrPPh30Sdwc7qcz_B88eEhbKGfN2riNPdgszqtzSP0pSr12JnMBecfGz0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9UwFD8BTIgvqIB4FbQSQ3jgkn30drvh6Ua9wQ-IMUB4IFnaro0LsEu4m1H-Af5tz-m6IaKJ4Wnddpa22znr-bWnvwPwJg10HhtEJwMpRZ9rLBEnCOpyOkx1FGjulgv29sXuIf94PDiegZ12L0zDD9FNuJFluP81GfhFbn8z8rPiO5p5IIaz8IALRFfkEX3tuKNo67FDW5zW_3EQ9LRCFMbTPXp7MLrjYd52WN2IM34EJ21bm0CT0-26Utv66g8ax3t25jEseE-UjRrVeQIzplyEpVGJKPz8J9tgLjbUTbovwvyeX4JfgutRXU0q-aMot5jCupjURc586m8my5w1ISJsYhlewRpupKqOSf2SFeW3Qrl4MSzi8470gmQLOjrITamUiinz1K9TRnPGKEn59urpMhyM3x-83e37bA59HVMoVchDboXUlO5aKGVNorixSnFudIL4Xkfo5-dWJxJBVpJH6JuECIa4tFoEXMdPYa6clOYZMKuMSJOY68CEXOXBMNY8yK2yUgxsHEQ92Gy_aqY90zkl3DjLWsSDrztzr7sH652o7-nfhFZb1ci8hU-zKAqJuQdxfA9ed7fRNmnBRZZmUqNMmAra2jbAJq00KtXVQv9W9DZTbKxTjH9Xn33-cOQKz_9f9BXMf3k3xtP9Ty_gITp5wyZIcxXmqsvarKEjVamXzmB-AYpJGew |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autotaxin%2C+bile+acid+profile+and+effect+of+ileal+bile+acid+transporter+inhibition+in+primary+biliary+cholangitis+patients+with+pruritus&rft.jtitle=Liver+international&rft.au=Hegade%2C+Vinod+S&rft.au=Pechlivanis%2C+Alexandros&rft.au=McDonald%2C+Julie+A+K&rft.au=Rees%2C+Douglas&rft.date=2019-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1478-3223&rft.eissn=1478-3231&rft.volume=39&rft.issue=5&rft.spage=967&rft.epage=975&rft_id=info:doi/10.1111%2Fliv.14069&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |